Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
Venture&Growth
Shoulder Innovations
Shoulder Innovations is a US-based medical device company that is commercializing a novel shoulder arthroplasty portfolio paired with an AI-enabled surgical planning software. The portfolio is anchored by Shoulder Innovations’ proprietary InSetTM glenoid fixing technology to solve the problem of
Venture&Growth
Okami Medical
Okami Medical, based in Aliso Viejo, California and founded in 2017 by the Inari team through the Inceptus Medical incubator, is a commercial-stage company focused on innovative solutions for peripheral vascular embolization across a wide range of conditions. The company’s
